What happened
Myungin Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$53.6M (+5.4% year on year), operating profit of US$19M (+9.8% year on year) and net income of US$16.7M (+16% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$53.6M |
|---|---|
| Revenue vs a year earlier | +5.4% |
| Operating profit | US$19M |
| Net income | US$16.7M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-31, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260731800602 → open original filing |
Source: DART. Information only, not investment advice.